Navigation Links
Butamax Granted Core Patent for Making Biobutanol and Distillers Grains; Offers Producers Efficient, Low-Cost Production of Biobutanol
Date:5/15/2012

WILMINGTON, Del., May 15, 2012 /PRNewswire/ -- Butamax™ Advanced Biofuels, LLC announced today that the United States Patent and Trademark Office (USPTO) has granted Butamax Patent Number 8,178,328. The '328 patent covers a highly efficient engineered pathway for producing isobutanol from recombinant microorganisms at commercial scale.  These novel microorganisms have been designed using advanced biotechnology to convert sugar to isobutanol.

(Logo: http://photos.prnewswire.com/prnh/20120209/MM50763LOGO )

The '328 patent also protects extraction and distillation of the isobutanol, as well as steps for recovering the solids (distillers grains) produced during isobutanol fermentation.  Protection of biobutanol processes that produce these grains is key in that distillers grains provide a significant economic advantage for Butamax's customers and provide local agriculture with a high-protein animal feed.  With these added protections having priority back to 2005, the '328 patent extends Butamax's foundational patent estate to span key value drivers for commercialization.

The USPTO granted the '328 patent in view of the art cited against Butamax's '188 and '899 patents in reexamination requests filed by Gevo.  This means that the USPTO has determined that the '328 patent is novel and inventive over all of the publications referenced in reexamination of the '188 and '889 patents.

"Grant of this new patent supports the Butamax view that the USPTO will ultimately affirm the '188 and '889 patents at the conclusion of the re-examination process," said Paul Beckwith, CEO Butamax.

Butamax will add the '328 patent to its ongoing litigation against Gevo.  A decision on Butamax's request for preliminary injunction against Gevo for infringing its '889 patent is expected in the near term and trial for that lawsuit (which also includes the '188 patent) is scheduled for April 2013; subsequent trials are expected for July 2014.

About Butamax

Butamax™ Advanced Biofuels, LLC, a joint venture between BP and DuPont, was formed to develop and commercialize biobutanol as a next generation renewable biofuel for the transport market. The company benefits from the synergy of DuPont's proven industrial biotechnology experience and BP's global fuels market knowledge. Butamax's proprietary technology offers a cost-advantaged manufacturing process for isobutanol with value from field to pump. For more information, visit www.butamax.com.

Butamax™ is a trademark of Butamax™ Advanced Biofuels, LLC.

Media Contact:
Cory Ziskind 646-277-1232


'/>"/>
SOURCE Butamax Advanced Biofuels, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Butamax™ Responds to Gevo Patent Infringement Lawsuit
2. Butamax™ and Fagen Announce Collaboration to Retrofit Ethanol Plants for Biobutanol Production
3. MonoSol Rx Granted Strategic US Patent for Thin Film Manufacturing Process
4. Memory Pharmaceuticals Granted Extension to Comply with NASDAQ Listing Requirements
5. ScinoPharm Granted US Patent for Novel Crystal Forms
6. BioLife Solutions Granted European Biopreservation Patent
7. GeneNews granted U.S. patent for Chagas disease based on Sentinel Principle(TM) platform
8. Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy
9. Valdoxan(R) Granted Marketing Authorisation for the Treatment of Major Depressive Episodes in Europe
10. Crisis Exemption Granted to Market Avipel(R) Corn Seed Treatment in Louisiana
11. VIASPACE Granted US Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... October 02, 2019 , ... Rapid ... pleased to announce that it has moved into a new, 5000 sqft, purpose-built, ... the new facility demonstrates the company's continuous commitment to quality research and service ...
(Date:9/24/2019)... ... 2019 , ... Drug resistance has been declared as one of the biggest ... one of the most serious concerns. Hong Kong cannot be spared from the worsening ... or a seven-fold of the figure in 2007 – the year the disease became ...
(Date:9/24/2019)... ... ... In the past three years, the National Science Foundation (NSF) has awarded ... of Mines & Technology that expands human understanding of the microbial world. The ... and yet strong layer which is commonly known as a biofilm. , The broad ...
(Date:9/17/2019)... ... September 17, 2019 , ... Geneticure, Inc., a Rochester ... today that the U.S. Patent and Trademark Office (USPTO) and European Patent Office ... class recommendations for hypertension treatment. , The patent applies to Geneticure’s first ...
Breaking Biology Technology:
(Date:10/3/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, ... stem cell treatment of knee osteoarthritis . The successful enrollment comes only a little ... Biopharma. , PSC CEO, Michael Dale, stated, “We are proud that as we celebrate ...
(Date:9/30/2019)... ALTO, Calif. (PRWEB) , ... September 30, 2019 ... ... public interest organization focused on molecular manufacturing and other transformative technologies, announced the ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells (hiPSCs) ... the development and diseases of the human heart, there is an increasing need for ... muscle cells to be clearly and easily recorded. A study released today in STEM ...
Breaking Biology News(10 mins):